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Abstract
A novel stereocontrolled approach has been developed for the syntheses of tashiromine and epitashiromine alkaloids from
cyclooctene β-amino acids. The synthetic concept is based on the azetidinone opening of a bicyclic β-lactam, followed by oxidative
ring opening through ring C–C double bond and reductive ring-closure reactions of the cis- or trans-cyclooctene β-amino acids.
Introduction
Indolizidine alkaloids are an important class of naturally occur-
ring compounds which have received considerable attention as a
result of their valuable physiological properties. A number of
representatives of this class exhibit glycosidase inhibitory
activity or antimetastatic, anticancer, antitumour or anti-HIV
properties [1-3]. A large number of natural products contain an
indolizidine framework, among them (−)-δ-coniceine,
(−)-swainsonine, indolizidine 167B [4-10], (+)-lentiginosine
[11-15], (+)-slaframine [16], (−)-elaeokanine C [17],
(+)-cyclizidine [18], lepadiformine [19], the highly oxygenated
(+)-castanospermine [20,21], or pumiliotoxin [22]. Figure 1
illustrates the structures of several such compounds.
Tashiromine is a natural indolizidine alkaloid isolated from
Maackia tashiroi (1990). Strategies for the synthesis of Figure 1: Some indolizidine alkaloids.
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Figure 4: Synthetic routes to (−)-tashiromine and (−)-epitashiromine.
indolizidine derivatives have received considerable interest
from synthetic and medicinal chemists (Figure 2). A number of
synthetic approaches have been described earlier for construc-
tion of the indolizidine framework; access to tashiromine in
racemic form can be achieved through the alkylation of succin-
imide, followed by ring closure via acyliminium intermediates
[23,24], the reduction of cyclized pyridinium salts [25],
iminium cascade cyclization [26], alkyne-mediated hydro-
formylation–cyclization [27], or electrophilic pyrolidinone
alkylation followed by ring closure [28,29]. Pyrrolidine alkyl-
ation and nucleophilic ring closure followed by C–C double
bond hydroboration [30] leads to racemic epitashiromine, as
does the N-alkylated succinimide transformation through the
corresponding indolizidinone [31].
Figure 2: Approaches to racemic tashiromine and epitashiromine.
Several synthetic procedures have also been developed for the
preparation of tashiromine or epitashiromine enantiomers.
(+)-Tashiromine has been synthetized from a pyrrolidinone
derivative through chiral Lewis acid-catalysed cyclization to
substituted pyrrolidinones [17], by the intramolecular cycliza-
tion of a chiral alkenylated pyrrolidinone, followed by hydrox-
ylation [32], or by the intramolecular ring closure of chiral
pyrrolidine diesters followed by ester and oxo group reduction
[33], while the syntheses of (+)-epitashiromine starts from a
chiral morpholine derivative, with nitrone 1,3-dipolar cycload-
dition and reduction [34] (Figure 3).
Figure 3: Synthetic routes to (+)-tashiromine and (+)-epitashiromine.
(−)-Tashiromine has been accessed through the ring closure of
difunctionalized acyclic chiral sulfonamide-based β-amino
acids [35], the cyclization of pyrrole derivatives with a chiral
side-chain [36], or the enantioselective arylation of pyrrole, fol-
lowed by saturation [37]. The transformation of chiral function-
alized pyrrole or pyrrolidine derivatives has served as the basis
of the construction of (−)-epitashiromine [38,39] (Figure 4).
The oxidative functionalization of cyclic β-amino acid deriva-
tives has been reported to be a convenient route for the prepar-
ation of N-heterocyclic β-amino acid derivatives [40,41] or for
the stereocontrolled synthesis of functionalized cispentacins
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Figure 5: Oxidative functionalizations of cyclic β-amino acids.
Scheme 1: Retrosynthesis of tashiromine and epitashiromine.
[42] and their acyclic counterparts [43,44] (Figure 5). The
oxidative ring cleavage of various vicinal diols and the transfor-
mation of the resulting dialdehyde intermediates has been effi-
ciently applied in recent years for the synthesis of a series of
valuable organic molecules [45-52]. In particular, Davies and
co-workers have utilized the oxidative ring opening of cyclic
vicinal diols followed by ring closure for access to pyrrolizidine
alkaloids [45].
Results and Discussion
We describe here a novel access route for the synthesis of
tashiromine and epitashiromine by starting from an unsaturated
bicyclic β-lactam. The retrosynthetic concept of the synthesis is
represented on Scheme 1 and was based on the lactam ring
opening, in continuation followed by oxidative ring opening of
the formed β-amino esters and by reductive ring closure as key
steps.
Bicyclic β-lactam (±)-1 [53,54] was first transformed by
azetidinone opening to the corresponding amino ester
hydrochloride (±)-2 [53,54], N-protection of which with benzyl
chloroformate (Z-Cl) afforded protected amino ester (±)-3 in
78% yield. In agreement with our earlier observations [40-42]
C–C double bond functionalization of the cyclooctene β-amino
ester via dihydroxylation with N-methyl morpholine N-oxide
(NMO) in the presence of OsO4 afforded the corresponding all-
cis dihydroxylated ethyl β-aminocyclooctanecarboxylate (±)-4
in 90% yield (for dihydroxylation, see also reference [54])
(Scheme 2). Amino ester (±)-4 was next subjected through its
vicinal diol moiety to oxidative ring opening with NaIO4 in
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Scheme 2: Synthesis of (±)-tashiromine ((±)-6).
MeOH at 20 °C, which resulted (monitored by TLC) in the
corresponding ring-opened unstable diformyl intermediate (I1),
which after work-up was immediately used without further
purification (for several similar types of acyclic diformyl inter-
mediates, see references [40,41,43,44]). Thus, the crude ma-
terial was submitted to catalytic hydrogenolysis and after
N-deprotection underwent double cyclization–reduction to
furnish indolizidine ester (±)-5 in 41% yield after purification
by chromatography.
Reduction of the ester group of (±)-5 with an excess of LiAlH4
in THF at 20 °C gave the corresponding tashiromine (±)-6 [35-
37], which was isolated in 48% yield after purification by
column chromatography (Scheme 2). The stereochemistry of
(±)-6 was unequivocally assigned by NMR data, which were
consistent with those reported [35-37].
A similar strategy was applied for the synthesis of
epitashiromine. On reaction with NaOEt in EtOH at 20 °C,
ethyl cis-β-aminocyclooctenecarboxylate (±)-3 underwent
epimerization at C-1, leading after 18 h to an equilibrium mix-
ture of cis and trans amino esters (1:1 ratio determined by
1H NMR on the crude mixture), the required trans isomer (±)-7
being separated from the cis counterpart and isolated in a yield
of 48% by means of column chromatography. Dihydroxylation
of (±)-7 with NMO/OsO4 next afforded an oily mixture of cis
and trans dihydroxylated cyclooctane β-amino esters (diastereo-
meric mixture of (±)-8) in 77% overall yield after column chro-
matography. Our attempts to separate this nearly 1:1 mixture of
the two dihydroxylated stereoisomers (determined on the basis
of 1H NMR data) failed, but the mixture could be applied in the
next ring-opening oxidation step, since it gave only one open-
chain diformyl intermediate I2.
Similarly to the cis isomer, this unstable dialdehyde intermedi-
ate was subjected without isolation to catalytic hydrogenolysis,
followed by reductive cyclization, to give the corresponding
indolizidine ester (±)-9 in 40% yield. Finally, ester reduction
with LiAlH4 in THF resulted in epitashiromine (±)-10
[32,34,39] in 53% yield after isolation by chromatography
(Scheme 3). The stereochemistry of (±)-epitashiromine was
assigned by NMR data, which were in agreement with those
reported [32,34,39].
Conclusion
In summary, a novel stereocontrolled efficient method has been
presented for the synthesis of tashiromine and epitashiromine
alkaloids in six or seven steps, based on the preparation of cis or
trans cyclooctene β-amino esters, followed by their oxidative
ring cleavage and double reductive ring-closure reactions.
Experimental
General procedure for the Z-protection of
amino esters
To a solution of amino ester hydrochloride ((±)-2 or (−)-2) [29]
(17.8 mmol) in THF (40 mL), Et3N (9 mL) was added at 0 °C,
followed by 7.8 mL (1 equivalent) of Z-Cl (a 50% solution in
toluene). The mixture was stirred for 14 h at 20 °C, and then
was diluted with EtOAc (120 mL). The organic layer was
washed with H2O (3 × 60 mL), dried (Na2SO4), and concen-
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Scheme 3: Synthesis of (±)-epitashiromine ((±)-10).
trated under reduced pressure. The crude material was purified
by column chromatography on silica gel (n-hexane/EtOAc 4:1),
affording the amino ester.
General procedure for the dihydroxylation of
amino esters
To a solution of cis or trans Z-protected amino ester ((±)-3,
(−)-3 or (±)-7) (2.9 mmol) in acetone (30 mL) and H2O (1 mL),
NMO (1.5 equivalents) and 2% OsO4 in t-BuOH (0.7 mL) were
added and the mixture was stirred at 20 °C for 4 h. A saturated
aqueous solution of Na2SO3 (40 mL) was then added, the mix-
ture was extracted with CH2Cl2 (3 × 30 mL), and the organic
layer was dried (Na2SO4) and concentrated under reduced pres-
sure. The crude product was purified by column chromatog-
raphy on silica gel (n-hexane/EtOAc 1:4) to give the dihydroxy-
lated amino ester.
General procedure for epimerization of the
cis-amino ester
To a solution of cis N-protected amino ester ((±)-3 or (−)-3)
(3.3 mmol) in EtOH (30 mL), EtONa (1.5 equivalents) was
added at 0 °C and the mixture was stirred at 20 °C for 18 h.
H2O (70 mL) was then added, the mixture was extracted with
CH2Cl2 (3 × 30 mL), and the organic layer was dried over
Na2SO4 and concentrated under reduced pressure. The crude
material was purified by column chromatography on silica gel
(n-hexane/EtOAc 9:1) to give the trans isomer as a colourless
oil.
General procedure for the oxidative ring
opening/reductive ring closure of
dihydroxylated amino esters
To a solution of dihydroxylated amino ester ((±)-4, (±)-8 or
(−)-8) (2.46 mmol) in MeOH (25 mL), NaIO4 (2 equivalents)
was added and the mixture was stirred at 20 °C for 45 min. It
was then diluted with H2O (50 mL) and extracted with CH2Cl2
(3 × 20 mL). The organic layer was dried (Na2SO4) and
concentrated under reduced pressure. The crude mixture was
dissolved in EtOAc (30 mL), Pd/C (150 mg) was added and the
mixture was stirred at 20 °C for 16 h. The catalyst was next
filtered off through Celite. The crude mixture was then purified
by column chromatography on silica gel (CH2Cl2/MeOH 95:5
or CH2Cl2/MeOH 9:1) to give the indolizidine derivative.
General procedure for reduction of the ester
To a solution of indolizidine carboxylate ((±)-5, (±)-9 or (−)-9)
(1 mmol) in dry THF (15 mL), LiAlH4 (5 equivalents) was
added at 0 °C and the mixture was stirred at 20 °C for 4 h. It
was then cooled to 0 °C, H2O (2 mL) was added dropwise and
the solid formed was filtered off through Celite. The filtrate was
extracted with CH2Cl2 (3 × 15 mL), and the combined organic
layers were dried (Na2SO4) and concentrated under reduced
pressure. The crude oil was purified by column chromatog-
raphy on silica gel (CH2Cl2/MeOH/NH4OH 90:8:2 or CH2Cl2/
MeOH/NH4OH 90:5:5) to give the alkaloid.
Ethyl (1R*,2S*)-2-(benzyloxycarbonylamino)cyclooct-5-
enecarboxylate ((±)-3)
A colourless oil (Rf 0.6, n-hexane/EtOAc 4:1); yield: 78%;
1H NMR (400 MHz, CDCl3) δ 1.28 (t, J = 7.1 Hz, 3H, CH3),
1.76–1.87 (m, 2H, CH2), 1.88–1.97 (m, 1H, CH2), 1.98–2.07
(m, 1H, CH2), 2.09–2.18 (m, 2H, CH2), 2.22–2.31 (m, 1H,
CH2), 2.43–2.52 (m, 1H, CH2), 2.82–2.89 (m, 1H, H-1),
4.12–4.21 (m, 2H, OCH2), 4.22–4.30 (m, 1H, H-2), 5.08 (s, 2H,
OCH2), 5.30 (brs, 1H, N-H), 5.60–5.74 (m, 2H, H-5 and H-6),
7.33–7.48 (m, 5H, Ar-H); 13C NMR (100 MHz, DMSO) δ 14.9,
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24.4, 25.1, 26.6, 32.3, 46.4, 52.1, 60.6, 66.1, 128.5, 128.6,
129.2, 129.5, 130.7, 138.0, 156.3, 174.5; anal. calcd for
C19H25NO4: C, 68.86; H, 7.60; N, 4.23; found: C, 68.59; H,
7.31; N, 3.93.
Ethyl (1R*,2S*,5R*,6S*)-2-(benzyloxycarbonylamino)-5,6-
dihydroxycyclooctanecarboxylate ((±)-4)
A colourless oil (Rf 0.4, n-hexane/EtOAc 1:4); yield: 90%;
1H NMR (400 MHz, CDCl3) δ 1.26 (t, J = 7.15 Hz, 3H, CH3),
1.62–1.94 (m, 4H, CH2), 1.97–2.28 (m, 4H, CH2), 2.77–2.82
(m, 1H, H-1), 3.83–3.89 (m, 2H, H-5 and H-6), 4.02–4.10 (m,
1H, H-2), 4.11–4.19 (m, 2H, OCH2), 5.09 (m, 2H, OCH2), 5.49
(brs, 1H, N-H), 7.36–7.48 (m, 5H, Ar-H); 13C NMR (100 MHz,
DMSO) δ 14.8, 21.2, 26.9, 28.5, 29.0, 45.4, 51.6, 60.7, 65.9,
72.3, 72.4, 128.4, 128.5, 129.1, 138.1, 156.3, 174.6; anal. calcd
for C19H27NO6: C, 62.45; H, 7.45; N, 3.83; found: C, 62.19; H,
7.10; N, 4.13.
Ethyl (8R*,8aS*)-octahydroindolizine-8-carboxylate ((±)-5)
A yellow oil (Rf 0.55, CH2Cl2/MeOH 95:5); yield: 41%;
1H NMR (400 MHz, CDCl3) δ 1.27 (t, J = 7.15 Hz, 3H, CH3),
1.46–1.53 (m, 2H, CH2), 1.57–1.92 (m, 5H, CH2), 1.99–2.10
(m, 3H, CH2), 2.13–2.20 (m, 1H, CH2), 2.25–2.31 (m, 1H,
H-8), 3.03–3.10 (m, 2H, CH2 and H-8a); 13C NMR (100 MHz,
CDCl3) δ 14.6, 20.9, 25.1, 29.5, 30.1, 48.4, 52.6, 54.4, 60.6,
65.6, 174.6; MS (ESI) m/z: 198.5 [M + 1]; anal. calcd for
C11H19NO2: C, 66.97; H, 9.71; N, 7.10; found: C, 66.60; H,
10.02; N, 7.39.
((8R*,8aS*)-Octahydroindolizin-8-yl)methanol;
((±)-tashiromine (±)-6) [35-37]
A yellow oil (Rf 0.45, CH2Cl2/MeOH/NH4OH 90:8:2); yield:
48%; 1H NMR (400 MHz, CDCl3) δ 1.00–1.11 (m, 1H, CH2),
1.42–1.53 (m, 2H, CH2), 1.58–1.83 (m, 5H, CH2), 1.84–1.99
(m, 3H, CH2), 2.04–2.11 (m, 1H, CH2), 3.03–3.10 (m, 2H,
N-CH), 3.41–3.46 (m, 1H, OCH2), 3.59–3.64 (m, 1H, OCH2);
13C NMR (100 MHz, CDCl3) δ 21.1, 25.5, 28.0, 29.4, 44.9,
53.1, 54.5, 66.0, 66.9; MS (ESI) m/z: 156.6 [M + 1]; anal. calcd
for C9H17NO: C, 69.63; H, 11.04; N, 9.02; found: C, 69.28; H,
10.70; N, 8.76.
Ethyl (1S*,2S*)-2-(benzyloxycarbonylamino)cyclooct-5-
enecarboxylate ((±)-7)
A colourless oil (Rf 0.55, n-hexane/EtOAc 4:1); yield: 48%;
1H NMR (400 MHz, DMSO) δ 1.18 (t, J = 7.10 Hz, 3H, CH3),
1.55–1.64 (m, 2H, CH2), 1.73–1.97 (m, 2H, CH2), 2.04–2.19
(m, 2H, CH2), 2.33–2.47 (m, 2H, CH2), 2.68–2.75 (m, 1H,
H-1), 3.88–4.02 (m, 3H, OCH2 and H-2), 4.96–5.02 (m, 2H,
OCH2), 5.53–5.60 (m, 2H, H-5 and H-6), 7.30–7.44 (m, 5H,
Ar-H); 13C NMR (100 MHz, DMSO) δ 14.8, 24.5, 25.1, 29.2,
33.8, 49.2, 52.1, 60.4, 65.9, 128.0, 128.4, 129.0, 129.1, 130.7,
138.2, 156.9, 174.5; anal. calcd for C19H25NO4: C, 68.86; H,
7.60; N, 4.23; found: C, 68.57; H, 7.28; N, 3.97.
Ethyl (8S*,8aS*)-octahydroindolizine-8-carboxylate ((±)-9)
A yellow oil (Rf 0.45, CH2Cl2/MeOH 4:1); yield: 40%;
1H NMR (400 MHz, CDCl3) δ 1.28 (t, J = 7.15 Hz, 3H, CH3),
1.28–1.33 (m, 1H, CH2), 1.42–1.55 (m, 2H, CH2), 1.58–1.64
(m, 1H, CH2), 1.68–1.86 (m, 3H, CH2), 2.02–2.18 (m, 3H,
CH2), 2.23–2.27 (m, 1H, CH2), 2.78–2.81 (m, 1H, H-8),
3.04–3.10 (m, 2H, CH2 and H-8a), 4.09–4.17 (m, 2H, OCH2);
13C NMR (100 MHz, DMSO) δ 15.1, 21.2, 22.6, 26.8, 27.3,
42.0, 53.4, 55.0, 60.5, 64.9, 170.4; MS (ESI) m/z: 198.7 [M +
1]; anal. calcd for C11H19NO2: C, 66.97; H, 9.71; N, 7.10;
found: C, 67.28; H, 9.40; N, 6.78.
((8S*,8aS*)-Octahydroindolizin-8-yl)methanol; ((±)-
epitashiromine, (±)-10) [32,34,39]
A yellow oil (Rf 0.45, CH2Cl2/MeOH/NH4OH 88:8:4); yield:
53%; 1H NMR (400 MHz, CDCl3) δ 1.56–1.62 (m, 2H, CH2),
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1.65–1.74 (m, 4H, CH2), 1.97–2.12 (m, 5H, CH2), 2.20–2.28
(m, 1H, H-8), 2.94–3.00 (m, 1H, CH2), 3.08–3.14 (m, 1H,
N-CH), 3.70–3.75 (m, 1H, OCH2), 4.13–4.19 (m, 1H, OCH2);
13C NMR (100 MHz, CDCl3) δ 21.2, 23.7, 26.3, 30.1, 35.7,
54.0, 54.9, 66.0, 66.8; MS (ESI) m/z: 156.4 [M + 1]; anal. calcd
for C9H17NO: C, 69.63; H, 11.04; N 9.02; found: C, 69.30; H,
10.71; N, 8.79.
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